Publications, Pharmaceutical

The Potential and Challenge of Nasal Vaccination

Intranasal vaccination is an innovative method of vaccine delivery that involves administering vaccines through the nasal cavity. It is a safe and effective way of immunization that offers several benefits over traditional injection methods. This approach is particularly useful for respiratory infections, where the site of infection is in the nose and throat.

The development of intranasal vaccines is a promising area of research, with potential implications for the management of various respiratory illnesses. The field is evolving rapidly, and ongoing research and development will be essential to realize the full potential of nasal vaccines.

The use of intranasal vaccines has been gaining popularity due to their ease of administration and the lack of need for needles. This makes them a practical option for mass immunization campaigns and for people who have a fear of needles. Additionally, intranasal vaccines can stimulate both mucosal and systemic immunity, providing a broader and more robust immune response.

The COVID-19 pandemic rekindled interest in intranasal vaccine development, as nasal vaccines are seen as logical for pathogens that enter through the nose. Intranasal vaccines could be an efficient long-term solution for managing the SARS-CoV-2 virus. Several intranasal vaccines have already been approved for use, and many more are in development. The attractions of intranasal vaccination are not limited to COVID-19 but also extend to other indications such as respiratory syncytial virus (RSV).

However, for the safe and effective delivery of intranasal vaccines, certain requirements must be met. This includes optimizing the formulation of the vaccine to ensure stability and potency, choosing the appropriate delivery device, and ensuring the device’s design and performance meet regulatory requirements.

Intranasal vaccines can be formulated as either a liquid or powder, depending on the vaccine’s properties and stability. The choice of delivery device is also critical, with various options available, including nasal spray pumps and nasal powder devices.

Aptar Pharma offers cutting-edge solutions and end-to-end support services to support commercialization of new nasal vaccine projects, including expertise in nasal formulation, product development and device selection, allowing for a streamlined and efficient vaccine development process.

This article reviews the potential of intranasal vaccination as well as some of the development challenges involved.

For more information on ONdrugDelivery.

Download Publication "The Potential and Challenge of Nasal Vaccination"
Author(s): Dr Julie Suman Nektaria Karavas
24 Apr 2023

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

6 Nov 2023

Nasal Inhalation Testing: IPAC-RS Droplet Size Analysis

Publications, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
13 Oct 2023

Nasal Drug Delivery: In Vitro Anatomical Models

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
4 Aug 2023

Aptar Pharma Discusses Intranasal Drug Delivery with PharmTech

Podcasts, Pharmaceutical, Brand Differentiation, Market Insights, Product Solutions, Device Innovations

Read More
3 Jul 2023

Nasal Spray Orientation & Sumatriptan Exposure using PK Modelling

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
1 2 3 22

Request Access


Requesting access to The Potential and Challenge of Nasal Vaccination.

  • This field is for validation purposes and should be left unchanged.
Back To Top